New French biomed center operational

2 April 2006

The major Eurasante biomedical center in northern France in the Nord-Pas de Calais, developed over a 10-year incubation period by the Eurasante agency, is now fully operational linking 700 regional companies of which 75 are located on this site. Last year, the park added 18 new companies, bringing the total number of jobs to some 20,000.

The new arrivals have included biotechnology enterprises, medical equipment and nutritional products companies. A number of new organizations will move to the site in 2006 including the regional health promotion council, the MRPS. A capital injection of new funding this year will also aim to promote mixed public-private companies specializing in nutrition, health and issues of longevity. One of the leading firms on the site, Maco Pharma, has increased its workforce from 300 to 1,800 in the past five years. The site has also had the effect of encouraging an increase volume of health care congresses to be channelled into the neighboring city of Lille, a key center for university-based medical and pharmaceutical research.

This article is accessible to registered users, to continue reading please register for free.  A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Login to your account

Become a subscriber

 

£820

Or £77 per month

Subscribe Now
  • Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
  • Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
  • Daily roundup of key events in pharma and biotech.
  • Monthly in-depth briefings on Boardroom appointments and M&A news.
  • Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK





Today's issue

Company Spotlight